155 related articles for article (PubMed ID: 14691916)
1. Secretory carcinoma of the breast: a distinct variant of invasive ductal carcinoma assessed by comparative genomic hybridization and immunohistochemistry.
Diallo R; Schaefer KL; Bankfalvi A; Decker T; Ruhnke M; Wülfing P; Jackisch C; Luttges J; Sorensen PH; Singh M; Poremba C
Hum Pathol; 2003 Dec; 34(12):1299-305. PubMed ID: 14691916
[TBL] [Abstract][Full Text] [Related]
2. Secretory carcinoma of the breast: a genetically defined carcinoma entity.
Diallo R; Tognon C; Knezevich SR; Sorensen P; Poremba C
Verh Dtsch Ges Pathol; 2003; 87():193-203. PubMed ID: 16888913
[TBL] [Abstract][Full Text] [Related]
3. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
4. Differential amplification and overexpression of HER-2/neu, p53, MIB1, and estrogen receptor/progesterone receptor among medullary carcinoma, atypical medullary carcinoma, and high-grade invasive ductal carcinoma of breast.
Xu R; Feiner H; Li P; Yee H; Inghirami G; Delgado Y; Perle MA
Arch Pathol Lab Med; 2003 Nov; 127(11):1458-64. PubMed ID: 14567723
[TBL] [Abstract][Full Text] [Related]
5. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
Latta EK; Tjan S; Parkes RK; O'Malley FP
Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
[TBL] [Abstract][Full Text] [Related]
6. Expression of E-cadherin and c-erbB-2/HER-2/neu oncoprotein in high-grade breast cancer.
Turashvili G; Bouchalova K; Bouchal J; Kolar Z
Cesk Patol; 2007 Jul; 43(3):87-92. PubMed ID: 17821836
[TBL] [Abstract][Full Text] [Related]
7. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial DNA alterations correlate with the pathological status and the immunological ER, PR, HER-2/neu, p53 and Ki-67 expression in breast invasive ductal carcinoma.
Lin CS; Chang SC; Ou LH; Chen CM; Hsieh SS; Chung YP; King KL; Lin SL; Wei YH
Oncol Rep; 2015 Jun; 33(6):2924-34. PubMed ID: 25845386
[TBL] [Abstract][Full Text] [Related]
9. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
[TBL] [Abstract][Full Text] [Related]
10. Secretory Breast Carcinoma: A Histopathologic and Genomic Spectrum Characterized by a Joint Specific ETV6-NTRK3 Gene Fusion.
Del Castillo M; Chibon F; Arnould L; Croce S; Ribeiro A; Perot G; Hostein I; Geha S; Bozon C; Garnier A; Lae M; Vincent-Salomon A; MacGrogan G
Am J Surg Pathol; 2015 Nov; 39(11):1458-67. PubMed ID: 26291510
[TBL] [Abstract][Full Text] [Related]
11. Centromere 17 copy number alteration: negative prognostic factor in invasive breast cancer?
Petroni S; Addati T; Mattioli E; Caponio MA; Quero C; Rubini V; Giotta F; Simone G
Arch Pathol Lab Med; 2012 Sep; 136(9):993-1000. PubMed ID: 22938586
[TBL] [Abstract][Full Text] [Related]
12. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
13. Study on breast carcinoma Her2/neu and hormonal receptors status assessed by automated images analysis systems: ACIS III (Dako) and ScanScope (Aperio).
Słodkowska J; Filas V; Buszkiewicz E; Trzeciak P; Wojciechowski M; Koktysz R; Staniszewski W; Breborowicz J; Rojo MG
Folia Histochem Cytobiol; 2010 Jan; 48(1):19-25. PubMed ID: 20529811
[TBL] [Abstract][Full Text] [Related]
14. Routine assessment of hormonal receptor and her-2/neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer.
Nyagol J; Nyong'o A; Byakika B; Muchiri L; Cocco M; de Santi MM; Spina D; Bellan C; Lazzi S; Kostopoulos I; Luzi P; Leoncini L
Anal Quant Cytol Histol; 2006 Apr; 28(2):97-103. PubMed ID: 16637512
[TBL] [Abstract][Full Text] [Related]
15. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
Recăreanu F; Simionescu C; Georgescu CV; Pirici E
Rom J Morphol Embryol; 2011; 52(3 Suppl):1059-64. PubMed ID: 22119825
[TBL] [Abstract][Full Text] [Related]
16. Multicentric mammary carcinoma: evidence of monoclonal proliferation.
Middleton LP; Vlastos G; Mirza NQ; Eva S; Sahin AA
Cancer; 2002 Apr; 94(7):1910-6. PubMed ID: 11932891
[TBL] [Abstract][Full Text] [Related]
17. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach.
Ridolfi RL; Jamehdor MR; Arber JM
Mod Pathol; 2000 Aug; 13(8):866-73. PubMed ID: 10955453
[TBL] [Abstract][Full Text] [Related]
18. The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study.
Tong LC; Nelson N; Tsourigiannis J; Mulligan AM
Am J Surg Pathol; 2011 Apr; 35(4):545-52. PubMed ID: 21358301
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological features and genomic profiles of a group of secretory breast carcinomas in which progressive cases have more complex genomic features.
Lei T; Yang Y; Shi Y; Deng X; Peng Y; Wang H; Chen T
Diagn Pathol; 2022 Dec; 17(1):101. PubMed ID: 36585729
[TBL] [Abstract][Full Text] [Related]
20. Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: a study at a tertiary cancer center.
Murthy SS; Sandhya DG; Ahmed F; Goud KI; Dayal M; Suseela K; Rajappa SJ
Indian J Pathol Microbiol; 2011; 54(3):532-8. PubMed ID: 21934215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
